Related CAS #
807640-87-5 (free base)
1021686-80-5 (2HBr salt)
Synonym
JNJ26483327; JNJ 26483327; JNJ-26483327; BGB102; BGB-102; BGB 102.
IUPAC/Chemical Name
35-bromo-17-methoxy-5-methyl-11-oxa-2,5-diaza-1(4,6)-quinazolina-3(1,2)-benzenacycloundecaphane
InChi Key
JXDYOSVKVSQGJM-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H25BrN4O2/c1-27-8-4-3-5-9-29-21-11-17-19(12-20(21)28-2)24-14-25-22(17)26-18-10-16(23)7-6-15(18)13-27/h6-7,10-12,14H,3-5,8-9,13H2,1-2H3,(H,24,25,26)
SMILES Code
CN1CCCCCOC(C(OC)=C2)=CC3=C2N=CN=C3NC4=CC(Br)=CC=C4C1
Appearance
white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
457.36
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Konings IR, de Jonge MJ, Burger H, van der Gaast A, van Beijsterveldt LE,
Winkler H, Verweij J, Yuan Z, Hellemans P, Eskens FA. Phase I and pharmacological
study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients
with advanced solid tumours. Br J Cancer. 2010 Sep 28;103(7):987-92. doi:
10.1038/sj.bjc.6605867. Epub 2010 Sep 7. PubMed PMID: 20823884; PubMed Central
PMCID: PMC2965873.
2: Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. HER2
phosphorylation is maintained by a PKB negative feedback loop in response to
anti-HER2 herceptin in breast cancer. PLoS Biol. 2010 Dec 21;8(12):e1000563. doi:
10.1371/journal.pbio.1000563. Erratum in: PLoS Biol. 2016 Mar;14(3):e1002414.
PubMed PMID: 21203579; PubMed Central PMCID: PMC3006345.
3: Danhier F, Ucakar B, Vanderhaegen ML, Brewster ME, Arien T, Préat V.
Nanosuspension for the delivery of a poorly soluble anti-cancer kinase inhibitor.
Eur J Pharm Biopharm. 2014 Sep;88(1):252-60. doi: 10.1016/j.ejpb.2014.05.014.
Epub 2014 May 21. PubMed PMID: 24859391.
